Neoadjuvant chemotherapy for operable breast cancer

@article{Mieog2007NeoadjuvantCF,
  title={Neoadjuvant chemotherapy for operable breast cancer},
  author={J Sven D Mieog and Jos A van der Hage and Cornelius J.H. van de Velde},
  journal={British Journal of Surgery},
  year={2007},
  volume={94}
}
Neoadjuvant chemotherapy for early breast cancer can avoid mastectomy by shrinkage of tumour volume. This review assesses the effectiveness of neoadjuvant chemotherapy on clinical outcome. 
Neoadjuvant chemotherapy in non‐metastatic breast cancer: a study on practice trends in a regional cancer treatment service
Neoadjuvant chemotherapy (NACT) is increasingly used for managing locally advanced and high risk non‐metastatic breast cancer.
Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor
TLDR
The case for using neoadjuvant chemotherapy in muscle-invasive bladder cancer is advanced and preoperative chemotherapy in these patients would be likely to result in survival benefits similar to those seen in breast and colon cancers.
Preoperative taxane‐based chemotherapy in a standardized protocol for locally advanced breast cancer
TLDR
The feasibility of a standardized multidisciplinary protocol for the management of locally advanced breast cancer (LABC) and the accuracy of magnetic resonance imaging and positron emission tomography in predicting the extent of residual disease are evaluated.
Impact of the extent of pathologic complete response on outcomes after neoadjuvant chemotherapy
TLDR
The impact of breast and/or lymph node pCR on survival is examined and the importance of independent prognostic factor after NAC is examined.
Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery
TLDR
This study sought to evaluate the effect of NAC on surgical outcomes after the adoption of a “no‐ink‐on‐tumor” margin policy in patients undergoing primary BCS (PBSC).
Assessment and Localisation of Response to Primary Systemic Therapy in Breast Cancer
TLDR
In imaging and surgical issues associated with the increasing use of PST in the management of breast cancer, the role of imaging, with a special focus on ultrasound, is evaluated.
Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast Cancer
TLDR
Results from an ongoing phase 3 randomized trial will help to clarify the value of locoregional radiotherapy for patients with clinical N1 disease that becomes node negative after neoadjuvant chemotherapy.
Neoadjuvant chemotherapy: for whom?
Initially, neoadjuvant chemotherapy (NAC) was used in inflammatory breast cancers and inoperable tumors. More recently, indications have been spread to earlier stages and operable breast cancers. No
Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma
TLDR
The value of localized index node removal after neoadjuvant immunotherapy in patients with stage III melanoma, for use as a response indicator to guide the extent of completion lymph node dissection, is explored.
Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer.
TLDR
Practical management advice where NACT is considered and adopted is considered, with a focus on breast conservation surgery in patients who would otherwise require a mastectomy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer
TLDR
A meta‐analysis of studies that examined the results of SLNB after preoperative chemotherapy found that women with breast cancer are more frequently being treated with preoperative neoadjuvant chemotherapy.
Neoadjuvant chemotherapy in operable breast cancer.
TLDR
Tumour response, evaluated after two cycles of neoadjuvant chemotherapy, was significantly associated with dose and survival showed a slight non-significant advantage for the neoadedjuvant group, and survival plotted by actual dose was also similar.
Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response.
Primary, preoperative, or neoadjuvant chemotherapy was introduced in the early 1970s as part of an integrated therapeutic approach to treat inoperable locally advanced breast cancer. The approach
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
TLDR
The use of preoperative chemotherapy yields similar results in terms of PFS, OS, and locoregional control compared with conventional postoperative chemotherapy and enables more patients to be treated with breast-conserving surgery.
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).
TLDR
Breast-conserving therapy can be performed in more than half of all cases without alteration of survival, despite a non-negligible rate of local recurrences.
Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial
TLDR
Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy was effective against local/regional tumors in stage II breast cancer but was otherwise comparable to postoperative chemotherapy.
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
TLDR
Marginally statistically significant treatment-by-age interactions appear to be emerging for survival and DFS, suggesting that younger patients may benefit from preoperative therapy, whereas the reverse may be true for older patients.
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
  • H. Bear, S. Anderson, +11 authors N. Wolmark
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences.
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.
TLDR
Good clinical response to neoadjuvant chemotherapy is associated with superior DFS and OS, which supports the use of clinical response of primary breast cancer to neoadedjuvant therapy as a surrogate marker of survival benefit.
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
TLDR
A group of representatives from breast cancer clinical research groups in France, Germany, Italy, the United Kingdom, and the United States reviewed all available data on prospective randomized trials in this setting to address concern about the use of PST in routine practice.
...
1
2
3
4
5
...